ArticleCancer gene therapy2017
Apoptosis-inducing and antiproliferative effect by inhibition of miR-182-5p through the regulation of CASP9 expression in human breast cancer.
Article in Cancer gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 62 citations in OpenAlex.
- Antisense LNA GapmeR targeting hsa-piR-33195 induces antiproliferative and apoptotic effects on human acute myeloid leukemia.Medical oncology (Northwood, London, England) · 2025Article
- Variable roles of miRNA- and apoptosis-linked genes in invasive breast cancer: expression patterns, clinicopathological associations, and prognostic significance.Molecular biology reports · 2025Article
- Article
- Anti-cancer efficiency ofCytotechnology · 2025Article
- Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Effect of chitosan nanoparticles conjugated with the cell free supernatant of Bifidobacterium bifidum on the expression of genes related to colorectal cancer in colon adenocarcinoma (Caco-2) cell line.BMC gastroenterology · 2025Article
- Gallic acid ameliorates LPS-induced memory decline by modulating NF-κB, TNF-α, and Caspase 3 gene expression and attenuating oxidative stress and neuronal loss in the rat hippocampus.Metabolic brain disease · 2024Article
- Focused cancer pathway analysis revealed unique therapeutic targets in retinoblastoma.Medical oncology (Northwood, London, England) · 2024Article
- Jozimine AInternational journal of molecular sciences · 2024Article
- Using published pathway figures in enrichment analysis and machine learning.BMC genomics · 2023Article
- MicroRNAs as Molecular Biomarkers for the Characterization of Basal-like Breast Tumor Subtype.Biomedicines · 2023Review
- The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target.Cancer cell international · 2023Review
- Impact of magnesium sulfate therapy in improvement of renal functions in high fat diet-induced diabetic rats and their offspring.Scientific reports · 2023Article
- The signature of pyroptosis-related gene prognostic and immune microenvironment in adrenocortical carcinoma.Frontiers in molecular biosciences · 2023Article
- Effects of hsa-piR-32877 Suppression with Antisense LNA GapmeRs on the Proliferation and Apoptosis of Human Acute Myeloid Leukemia Cells.International journal of molecular and cellular medicine · 2023Article
- Inhibition of miR-182-5p attenuates ROS and protects against myocardial ischemia-reperfusion injury by targeting STK17A.Cell cycle (Georgetown, Tex.) · 2022Article
- microRNA miR-133a as a Biomarker for Doxorubicin-Induced Cardiotoxicity in Women with Breast Cancer: A Signaling Pathway Investigation.Cardiovascular toxicology · 2022Article
- Pyroptosis-related molecular classification and immune microenvironment infiltration in breast cancer: A novel therapeutic target.Journal of cellular and molecular medicine · 2022Article
- A Novel Pyroptosis-Related Prognostic Signature for Risk Stratification and Clinical Prognosis in Clear Cell Renal Cell Carcinoma.Disease markers · 2022Article
- CASP9 As a Prognostic Biomarker and Promising Drug Target Plays a Pivotal Role in Inflammatory Breast Cancer.International journal of analytical chemistry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in molecular medicine and gene therapy have offered new effective achievements in the treatment of cancers. One of the molecular research lines for the diagnosis and treatment of cancer is the use of microRNAs (miRNAs), which are single-stranded noncoding RNAs. miRNAs are involved in the post-transcriptional regulation of gene expression and have a role in the growth, differentiation, cell death and cancer development. One of the miRNAs that showed upregulation in breast cancer is miR-182-5p. Oncogenic features of miR-182-5p in some cancers were confirmed. In the present study, blockage of miR-182-5p was performed in human breast cancer cell line (MCF-7) using locked nucleic acid (LNA)-anti-miR. MTT (3-[4,5 dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay and annexin/propidium iodide staining at different time points after LNA-anti-miR-182-5p transfection were accomplished. Our results showed that miR-182-5p inhibition can reduce the viability of MCF-7 cells because of apoptosis induction, probably through the upregulation of CASP9. A western blot analysis revealed that the expression of CASP9 protein is associated with miR-182-5p inhibition. The CASP9 protein acts as an initiator caspase of apoptosis in the mitochondrial cell death pathway. Our results can be used in translational medicine for future investigation in breast cancer and approach treatment based on antisense therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.